Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.4
4.0
Journals
JoF
Special Issues
Recent Advances in Clinical Mycology
share announcement

Recent Advances in Clinical Mycology

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".

Deadline for manuscript submissions: 28 February 2026 | Viewed by 1929

Special Issue Editor

Dr. Christopher P. Eades

E-Mail Website
Guest Editor
Department of Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK
Interests: fungal disease; mycoses; clinical science; laboratory; diagnostics; antifungals

Special Issue Information

Dear Colleagues,

The Special Issue entitled "Recent Advances in Clinical Mycology" aims to explore the state-of-the-art in diagnostic and therapeutic approaches concerning invasive fungal diseases. The issue will explore the cutting edge of medical science in relation to the management of mycoses. The issue will have a broad focus, including both laboratory and clinical sciences, to offer our readers a definitive and relevant overview. We are particularly interested in showcasing trends at the forefront of the development of therapeutic and diagnostic approaches, including high quality translational science and novel avenues in the treatment of fungal diseases.

Reviews, original research, and communications will be welcome.

Dr. Christopher P. Eades
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fungal disease
  • mycoses
  • clinical science
  • laboratory
  • diagnostics
  • antifungals

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 704 KB  
Article
The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease
by Udari Welagedara, Jessica Price, Raquel Posso, Matt Backx and P. Lewis White
J. Fungi 2025, 11(9), 656; https://doi.org/10.3390/jof11090656 - 5 Sep 2025
Viewed by 804
Abstract
Background: The presence of (1→3)-β-D-Glucan (BDG) in serum may be indicative of invasive fungal disease (IFD), but even without IFD, elevated BDG can be associated with adverse patient outcomes. Methods: COVID-19-infected patients (n = 125) who were screened for IFD with [...] Read more.
Background: The presence of (1→3)-β-D-Glucan (BDG) in serum may be indicative of invasive fungal disease (IFD), but even without IFD, elevated BDG can be associated with adverse patient outcomes. Methods: COVID-19-infected patients (n = 125) who were screened for IFD with fungal biomarkers were evaluated to assess the prognostic value of BDG. BDG was correlated with patients’ mortality, considering the influences of IFD and anti-fungal therapy (AFT). Results: A BDG concentration > 31 pg/mL was associated with significant mortality in the absence of documented IFD and without subsequent antifungal therapy (≤31 pg/mL: 28% vs. >31 pg/mL: 91%; p = 0.0001). In patients without IFD but with BDG > 31 pg/mL, mortality dropped to 50% when AFT was administered. In patients with BDG > 31 pg/mL and neither IFD nor AFT, the average probability of death was 3.38-fold greater. Conclusions: Elevated serum BDG is associated with significant mortality in COVID-19-infected patients without IFD, irrespective of AFT. A BDG-associated proinflammatory response might be driving the high mortality. BDG serves as a prognostic marker in COVID-19-infected patients with or without IFD. When BDG is very low (≤31 pg/mL) the likelihood of death remains consistent with the background mortality rates for COVID-19 within the ICU. Full article
(This article belongs to the Special Issue Recent Advances in Clinical Mycology)
►▼ Show Figures

Figure 1

17 pages, 299 KB  
Article
Rare Mould Fungaemia at a Tertiary Academic Hospital in Athens, Greece: A 15-Year Survey and Literature Review
by Maria Siopi, Angeliki Alevra, Dimitrios Mitsopoulos, Spyros Pournaras and Joseph Meletiadis
J. Fungi 2025, 11(9), 644; https://doi.org/10.3390/jof11090644 - 1 Sep 2025
Viewed by 630
Abstract
Invasive infections caused by rare moulds (RM) are increasingly reported and often exhibit resistance to antifungal agents. Their epidemiology varies regionally, yet data from Greece are scarce. To address this gap, we conducted a 15-year retrospective study of RM fungaemia at a tertiary [...] Read more.
Invasive infections caused by rare moulds (RM) are increasingly reported and often exhibit resistance to antifungal agents. Their epidemiology varies regionally, yet data from Greece are scarce. To address this gap, we conducted a 15-year retrospective study of RM fungaemia at a tertiary academic hospital in Athens, Greece. All microbiologically confirmed cases in hospitalised patients between 2010 and 2024 were reviewed. Demographic and clinical data were retrieved from medical records. Incidence rates were calculated per 1000 admissions and 10,000 bed-days. Isolates were morphologically identified and, when available, molecularly characterised and tested for antifungal susceptibility according to EUCAST guidelines. Eight RM fungaemia episodes (0.8% of total fungaemias) were identified, with an incidence of 0.01/1000 admissions and 0.03/10,000 bed-days, without bacterial co-infections. Haematological malignancies (62%) were the most common underlying condition. Fusarium spp. were the predominant pathogens (6/8), followed by single cases due to Lomentospora prolificans and Acremonium spp. Amphotericin B showed the highest in vitro activity against Fusarium isolates (MIC 0.5–1 mg/L), followed by voriconazole (MICs 2–8 mg/L) whereas other azoles showed no in vitro activity (MICs ≥ 8 mg/L). Half of the infections were breakthrough, whereas in 3/8 cases, the diagnosis was established post-mortem (n = 2) or post-discharge. Among the five patients who received treatment, the crude mortality rate was 60%. This first epidemiological report on RM fungaemia in Greece highlights the predominance of Fusarium spp., the frequency of breakthrough infections, and the challenges in early diagnosis and management. Increased clinical awareness and regional surveillance are essential for optimising outcomes. Full article
(This article belongs to the Special Issue Recent Advances in Clinical Mycology)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop